U.S. FDA Accepts sNDA and Grants Priority Review to Bayer’s Lynkuet® (elinzanetant) for a New Indication for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Endocrine Therapy Related to Breast Cancer
Today Bayer announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) and granted Priority Review designation for Lynkuet® (elinzanetant) under investigation for the treatment of moderate to severe vasomotor symptoms (VMS, also kn…